Critical care medicine · 1992
Hemodynamic effects of dobutamine in an intact animal model.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vernon D D, Garrett J S, Banner W, Dean J M
Аннотация
BACKGROUND AND METHODS: Actions of dobutamine at the beta 1, beta 2, and alpha 1 adrenoreceptors were studied in anesthetized dogs. Six animals received dobutamine (at infusion rates of 0 to 160 micrograms/kg/min) with and without beta-adrenergic receptor blockade. Five animals received phenylephrine (0 to 16 micrograms/kg/min), with and without concurrent dobutamine (20 micrograms/kg/min); this procedure was repeated in five animals after beta-blockade.
RESULTS: Dobutamine (10 to 160 micrograms/kg/min) increased heart rate (HR), cardiac output, and left ventricular change in pressure over time, and decreased systemic vascular resistance. beta-blockade prevented only dobutamine-induced changes in HR. Mean arterial pressure (MAP), unaffected by dobutamine alone, decreased with concurrent beta-blockade. Phenylephrine (1 to 16 micrograms/kg/min)-induced increases in MAP were unaffected by dobutamine; with beta-blockade, phenylephrine reduced MAP. Dobutamine prevented a phenylephrine-induced increase in systemic vascular resistance, an effect eliminated by beta-adrenergic receptor blockade.
CONCLUSIONS: Dobutamine appeared to be an agonist at the beta 1- and beta 2-adrenoreceptors and at the myocardial alpha-adrenoreceptor. Dobutamine appeared to be an alpha-adrenergic receptor antagonist in the peripheral vasculature.
RESULTS: Dobutamine (10 to 160 micrograms/kg/min) increased heart rate (HR), cardiac output, and left ventricular change in pressure over time, and decreased systemic vascular resistance. beta-blockade prevented only dobutamine-induced changes in HR. Mean arterial pressure (MAP), unaffected by dobutamine alone, decreased with concurrent beta-blockade. Phenylephrine (1 to 16 micrograms/kg/min)-induced increases in MAP were unaffected by dobutamine; with beta-blockade, phenylephrine reduced MAP. Dobutamine prevented a phenylephrine-induced increase in systemic vascular resistance, an effect eliminated by beta-adrenergic receptor blockade.
CONCLUSIONS: Dobutamine appeared to be an agonist at the beta 1- and beta 2-adrenoreceptors and at the myocardial alpha-adrenoreceptor. Dobutamine appeared to be an alpha-adrenergic receptor antagonist in the peripheral vasculature.